Investor Profile: CPT Capital — Thesis, Cheque Size & How to Apply

CPT Capital is a London-based venture firm that has been investing in alternative proteins longer than almost anyone else in the field. It is the venture arm of private equity pioneer Jeremy Coller's private family office, and it backs the companies driving the food and materials technology revolution. For founders building animal-free food, CPT Capital funding is patient, specialist capital from one of the earliest dedicated investors in the sector.

Thesis: the future of protein

CPT Capital invests exclusively in alternative proteins and sustainable food and materials technology. Its mandate spans five areas: plant-based proteins, biomass fermentation, recombinant proteins grown without the animal, cultivated meat grown from animal cells, and the enabling technologies and infrastructure needed to move away from a slaughtered-meat food system. The firm backs companies from seed through Series B and beyond, and describes its capital as long-term, supporting founders from early rounds all the way through to sale or IPO.

The mission behind the money is explicit. The firm is driven by the goal of ending factory farming, combining a philanthropic vision with disciplined venture investing.

Fund size and cheque size

CPT Capital's fund size is not publicly disclosed, which is typical for a family-office venture arm that does not raise external funds in the conventional way. It invests across seed, Series A and Series B stages, and a single standard cheque size is not publicly disclosed either. Founders should therefore approach CPT Capital on the strength of the technology and the round, rather than expecting a published ticket range, and be ready to discuss how patient capital fits a multi-year path to scale.

Notable portfolio companies

CPT Capital's early positions read like a history of the alternative protein sector. Its portfolio includes Beyond Meat and Impossible Foods in plant-based meat, Perfect Day in animal-free dairy protein, and Upside Foods in cultivated meat. More recent names include Redefine Meat, whose 3D-printing technology for animal-free meat CPT Capital backed in a $6 million round it led; ENOUGH, maker of the mycoprotein ingredient ABUNDA; Good Catch in plant-based seafood; Better Dairy; and Prolific Machines.

Partners and approach

CPT Capital was founded by Jeremy Coller, the pioneer behind Coller Capital, Europe's first private equity secondaries firm. The firm has been investing in alternative proteins since 2013, making it one of the earliest dedicated investors worldwide, and its team brings deep scientific diligence to sectors where technical claims need serious scrutiny. With a presence spanning the United Kingdom, the United States, Singapore, Israel and the Netherlands, it invests globally rather than in a single market, and it works with strategic partners across the food industry to support its companies.

How to apply for funding

CPT Capital publishes a direct contact route rather than an application portal. Its official investments page invites founders to share investment opportunities by emailing [email protected], and its website is cptcap.com. A strong approach explains which of the firm's five investment areas the company fits, the scientific basis of the product, evidence of taste, cost or scale progress, and the stage and size of the round. Given the firm's scientific diligence, founders should be ready for technical questions early in the conversation.